Lucence

Call Directions Website Contact the practice

Lucence Lucence is a precision health company committed to earlier detection for better health.

Lucence makes ultrasensitive non-invasive liquid biopsy tests to provide doctors and their patients life-changing information to enable earlier detection and effective treatment. Headquartered in Palo Alto and Singapore, Lucence supplies personalized cancer care services through twin CLIA-licensed laboratories in the United States and Singapore.

Last call to register! Join us for a live webinar exploring the emerging role of urine tumor DNA and RNA in urologic onc...
11/11/2026

Last call to register! Join us for a live webinar exploring the emerging role of urine tumor DNA and RNA in urologic oncology.

What can urine-based molecular testing mean for the management of bladder and prostate cancer? Hear from two experts bringing complementary perspectives:

Dr. Guru Sonpavde, MD, Medical Director of Genitourinary (GU) Oncology at Adventhealth Cancer Institute will share the clinical perspective, covering:
● Unmet needs in bladder cancer management
● The evolving role of MRD in muscle-invasive bladder cancer
● Emerging applications in non-muscle-invasive disease

Dr. Min-Han Tan, Lucence's Founding CEO and Medical Director, will explore:
● The science behind urine tumor DNA and RNA detection
● Advances in next-generation sequencing (NGS)
● Emerging clinical evidence and applications around earlier detection of prostate cancer

Join us from wherever you are! We've scheduled the sessions to work across the US and Asia:

📍 US & Canada: Wednesday, 11 November
5:00 PM Pacific | 8:00 PM Eastern

📍 Singapore, Hong Kong, Manila & Kuala Lumpur: Thursday, 12 November
9:00 AM GMT+8

Don't miss this opportunity to hear the clinical and technology perspectives, and take part in the conversation.

Register now: https://lnkd.in/geRr_72J

hashtag hashtag hashtag hashtag hashtag

Thank you to Lianhe Zaobao 联合早报 for the coverage. We are pleased to contribute to Singapore’s National Precision Medicin...
11/05/2026

Thank you to Lianhe Zaobao 联合早报 for the coverage. We are pleased to contribute to Singapore’s National Precision Medicine Programme and its aim to bring genomic sequencing to population scale.

Approximately 450,000 Singapore residents will be part of Phase III of Singapore’s National Precision Medicine (NPM) pro...
11/03/2026

Approximately 450,000 Singapore residents will be part of Phase III of Singapore’s National Precision Medicine (NPM) program.

The initiative aims to generate genomic and health data to deepen our understanding of disease and support more targeted approaches to healthcare.

Lucence has been selected as one of two sequencing providers for SG-INSIGHT, a cohort under Phase III, coordinated by Precision Health Research, Singapore (PRECISE).

Together with our partners QIAGEN and Ultima Genomics, we will support whole-genome sequencing performed in Singapore. As consortium lead, Lucence will provide end-to-end program management and local operational leadership, bringing together the technologies and expertise needed to support the program.

Much of today's genomic knowledge comes from populations of predominantly European ancestry. Generating more genomic evidence from Asian populations can help build a better understanding of how genetics influences health and disease.

This work also has relevance beyond Singapore, as governments across the region consider the role of genomics in future healthcare planning.

We are proud to contribute to this important national effort.

Read more: https://www.lucence.com/news-updates/lucence-advances-asian-genomics-with-clinical-grade-genome-sequencing-for-singapore%E2%80%99s-precision-medicine-programme

11/02/2026

Watch our ASEAN Multidisciplinary Brain Tumor Board webinar, which brought together 79 attendees from 7 countries and territories for a multidisciplinary discussion on brain tumour care.

Featuring case presentations by Dr. Daniel Chan of Icon Cancer Centre - ASEAN, Dr. Gabrielle Albay, and Dr. Swati Jain of National University Hospital, Singapore, the session explored clinical challenges and encouraged the exchange of perspectives among specialists across the region.

🎥 Watch the full webinar here: https://lnkd.in/gSJ9rRpb

A tissue biopsy may not tell the whole genomic story.Liquid biopsy can reveal alterations that tissue testing may miss, ...
10/28/2026

A tissue biopsy may not tell the whole genomic story.

Liquid biopsy can reveal alterations that tissue testing may miss, and vice versa. The two approaches offer complementary insights that can help inform cancer care.

Dr Gilberto Lopes, Chief of the Division of Medical Oncology and Associate Director of the Sylvester Comprehensive Cancer Center in Miami, Florida, shares how liquid biopsy is being used in clinical practice, from situations where tissue is insufficient to monitoring changes associated with treatment resistance.

Watch the video to hear his perspective - https://www.lucence.com/patient-stories/dr-gilberto-2026-1

A big thank you to the 79 attendees from 7 countries who joined our inaugural ASEAN Multidisciplinary Brain Tumor Board ...
10/22/2026

A big thank you to the 79 attendees from 7 countries who joined our inaugural ASEAN Multidisciplinary Brain Tumor Board meeting on Tuesday, hosted by Lucence CEO and Medical Director, Dr. Min-Han Tan.

Special thanks to Dr. Daniel Chan, Dr. Gabrielle Albay and Dr. Swati Jain for presenting their cases, the thoughtful discussions and the exchange of clinical perspectives across the region.

We look forward to continuing these conversations and learning together as a multidisciplinary community.

A favorable FDA advisory committee vote for a methylation-based MCED test is an important milestone. But it is not the f...
10/21/2026

A favorable FDA advisory committee vote for a methylation-based MCED test is an important milestone. But it is not the finish line.

Where does the field go from here?

Methylation has the most mature clinical evidence today. Mutations offer a different tumor-derived signal. Other approaches can add fragmentomics, proteins, RNA or viral DNA.

The bigger opportunity may be combining these signals to improve sensitivity without sacrificing the specificity needed for screening.

Our latest Clinical Insights article explores where MCED stands today, what the evidence tells us, and what it will take to move from promising detection to meaningful clinical benefit.

Read more: https://www.lucence.com/clinical-insights/mutations-and-methylation-where-does-the-evidence-stand

Why are some cancers more common in certain parts of the world?The answer isn't just genetics.From to***co and UV exposu...
10/07/2026

Why are some cancers more common in certain parts of the world?

The answer isn't just genetics.

From to***co and UV exposure to HPV, hepatitis B, betel quid, salt-preserved fish, and emerging environmental exposures like PFAS, cancer risk is shaped by the interaction between our environment, culture, and biology.

Our latest article explores what these patterns have taught us about cancer, and why screening is becoming more personalized.

Read more: https://www.lucence.com/clinical-insights/how-environment-culture-and-biology-shape-cancer-risk

Blood isn't the only place to look for cancer.Join Dr. Guru Sonpavde and Dr. Tan Min-Han to explore the emerging role of...
10/07/2026

Blood isn't the only place to look for cancer.

Join Dr. Guru Sonpavde and Dr. Tan Min-Han to explore the emerging role of urine tumor DNA (utDNA) in multi-cancer early detection for urologic cancers.

They’ll discuss where the field is headed and share new data supporting the approach.

🗓️ Nov 11, 2026
🕔 5:00 PM Pacific Time | 9:00 AM SGT
💻 Live on Zoom
Register now - https://zoom.us/webinar/register/WN_YhTzmpCSQ_2b4MeKKmW5GQ

Multi-cancer early detection is gaining attention globally, but what will it take for blood-based cancer screening to be...
09/30/2026

Multi-cancer early detection is gaining attention globally, but what will it take for blood-based cancer screening to become part of wider clinical practice?

South China Morning Post looks at the evolving MCED landscape, including developments in the US and perspectives from Hong Kong on the opportunities and questions that remain.

The article also highlights Gleneagles Hospital Hong Kong’s introduction of LucenceINSIGHT and its personalised screening options, with Dr Kenneth Tsang and our CEO Dr Tan Min-Han sharing their perspectives on the role of blood-based screening and the importance of continued clinical evidence.

Read the full article -

Doctors say more data is needed despite growing interest in detecting multiple cancers from a single blood sample.

Address

3520 W Bayshore Road
Palo Alto, CA
94303

Opening Hours

Monday 9am - 6pm
Tuesday 9am - 6pm
Wednesday 9am - 6pm
Thursday 9am - 6pm
Friday 9am - 6pm
Saturday 9am - 12pm

Telephone

+18885823623

Alerts

Be the first to know and let us send you an email when Lucence posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Lucence:

Shortcuts

Share

Nearby clinics